RxDoctor Payments Data

Elizabeth Dolin, DO

Pulmonary Disease · Tulsa, OKNPI 1861673493

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (46.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 80.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $4,792 and has fallen 99.6% since, to $17 in 2025.

$6,576in general payments, 2019–2025

Across 78 payments — averaging $84.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • GSK$253
  • AstraZeneca$188
  • Grifols USA, LLC$164
  • Jazz Pharmaceuticals Inc.$148
  • Genentech USA, Inc.$137
  • plus $371 from 8 others

What the payments were for

  • Travel & lodging$2,22334%
  • Food & beverage$1,31320%
  • Education$3,04046%

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,576 in reported general payments places this provider in the 70th percentile of 133 pulmonary disease providers in Oklahoma.

See all pulmonary disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$107,970
Medicare patients
499
Services billed
1,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter154$124,410
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr44$24,312
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$21,416
Breo ElliptaFluticasone/Vilanterol28$11,734
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$9,709
SymbicortBudesonide/Formoterol Fumarate16$3,964
Pulmicort FlexhalerBudesonide11$2,967
Albuterol Sulfate HfaAlbuterol Sulfate115$2,630
Wixela InhubFluticasone Propion/Salmeterol14$2,379
Montelukast Sodium36$1,187
Zolpidem Tartrate46$642
Prednisone73$325
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$264
Levofloxacin27$209
Clonazepam17$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$253$160,456226 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$188$28,34763 claims
Boehringer IngelheimStiolto Respimat$129$9,70921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 133 pulmonary disease providers in Oklahoma.

Other pulmonary disease in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →